In today’s crowded cannabis landscape, where “premium” is often used as a buzzword, The Medocann Group is setting a higher bar. Founded on nearly a century of family farming heritage and powered by state-of-the-art biotechnology, the Israeli company is redefining what premium truly means: consistency, purity, and precision at every stage of cultivation.
As part of a series of interviews focused on the expert contributors to Prohibition Partners’ newly launched Insights Hub we speak with Asaf Sella, Co-Founder and CEO, and Narkis Tessler, Chief of Strategy and Business Development, about Medocann’s philosophy, the technology behind their SMART indoor facility, and how they’re building long-term partnerships to take their craft cannabis to the global stage.
From pesticide-free cultivation and small-batch craftsmanship to patient loyalty and strategic international expansion, the discussion explores how Medocann is combining legacy, science, and vision to shape the future of ultra-premium cannabis.
“We approach cultivation not as farming alone, but as precision-driven biotechnology,” explains Asaf Sella, Co-Founder and CEO of Medocann. “Our SMART indoor facility is designed to maintain total environmental control — light, humidity, airflow, nutrients — allowing us to cultivate with zero pesticides and zero compromise.”
Unlike traditional greenhouse or Hybrid set-ups, Medocann’s closed-loop indoor system ensures uniformity across every batch, every time. The team leverages data analytics, advanced automation, and real-time plant monitoring to optimize for potency, terpene retention, and cleanliness. The result? Predictable excellence, backed by rigorous quality assurance protocols and built to EU-GMP standards.
Medocann’s products are anything but off-the-shelf. The company cultivates in small batches, hand-trims every flower, and slow-cures each harvest to protect the delicate trichomes holding the cannabinoid and terpene profile of each cultivar. This care is reflected in its two signature lines: SEVEN, a therapeutic-grade collection trusted by Israeli patients and clinicians, and SOLO, an ultra-premium craft collection for cannabis connoisseurs.
“There’s a lot of talk about premium in this space, but for us, it’s a discipline,” says Sella. “Every decision — from phenohunting to post-harvest handling — is made to serve the integrity of the plant and the experience of the consumer.”
With a mature domestic footprint in Israel — one of the most regulated and quality-driven cannabis markets globally — Medocann is now actively expanding its international presence.
“Our focus is on long-term partnerships with top-tier distributors who recognise the value of consistency, differentiation, and trust,” says Narkis Tessler, Chief of Strategy and Business Development. “We’re not looking to be just another supplier — we’re seeking partners who are committed to building long-term brand equity in the ultra-premium cannabis space.”
Known for their consistency and efficacy, Medocann’s SEVEN products quickly earn patient loyalty — driving repeat demand and helping partners build a strong, premium presence in their markets.
As regulatory frameworks evolve and consumer expectations sharpen, Medocann believes the cannabis industry is entering its quality-first era.
“We see cannabis moving from commodity to connoisseurship,” says Tessler. “The future belongs to companies that can consistently deliver safety, efficacy, and elevated experiences — not just once, but every single time.”
With its SMART indoor facility, pesticide-free commitment, and a growing international footprint, The Medocann Group is ready to meet that future — and help shape it.
Interested in partnering with Medocann? Visit www.medocann.com or contact us (info@medocann.com) to explore how we can bring ultra-premium craft cannabis to your market — together.
The post Cultivating Precision: Medocann’s Vision for Ultra-Premium Craft Cannabis on the Global Stage appeared first on Business of Cannabis.
Continue reading...
As part of a series of interviews focused on the expert contributors to Prohibition Partners’ newly launched Insights Hub we speak with Asaf Sella, Co-Founder and CEO, and Narkis Tessler, Chief of Strategy and Business Development, about Medocann’s philosophy, the technology behind their SMART indoor facility, and how they’re building long-term partnerships to take their craft cannabis to the global stage.
From pesticide-free cultivation and small-batch craftsmanship to patient loyalty and strategic international expansion, the discussion explores how Medocann is combining legacy, science, and vision to shape the future of ultra-premium cannabis.
Farming Meets Precision Engineering
“We approach cultivation not as farming alone, but as precision-driven biotechnology,” explains Asaf Sella, Co-Founder and CEO of Medocann. “Our SMART indoor facility is designed to maintain total environmental control — light, humidity, airflow, nutrients — allowing us to cultivate with zero pesticides and zero compromise.”
Unlike traditional greenhouse or Hybrid set-ups, Medocann’s closed-loop indoor system ensures uniformity across every batch, every time. The team leverages data analytics, advanced automation, and real-time plant monitoring to optimize for potency, terpene retention, and cleanliness. The result? Predictable excellence, backed by rigorous quality assurance protocols and built to EU-GMP standards.
Beyond “Premium” — A New Global Standard
Medocann’s products are anything but off-the-shelf. The company cultivates in small batches, hand-trims every flower, and slow-cures each harvest to protect the delicate trichomes holding the cannabinoid and terpene profile of each cultivar. This care is reflected in its two signature lines: SEVEN, a therapeutic-grade collection trusted by Israeli patients and clinicians, and SOLO, an ultra-premium craft collection for cannabis connoisseurs.
“There’s a lot of talk about premium in this space, but for us, it’s a discipline,” says Sella. “Every decision — from phenohunting to post-harvest handling — is made to serve the integrity of the plant and the experience of the consumer.”
Strategic Global Expansion with Select Partners
With a mature domestic footprint in Israel — one of the most regulated and quality-driven cannabis markets globally — Medocann is now actively expanding its international presence.
“Our focus is on long-term partnerships with top-tier distributors who recognise the value of consistency, differentiation, and trust,” says Narkis Tessler, Chief of Strategy and Business Development. “We’re not looking to be just another supplier — we’re seeking partners who are committed to building long-term brand equity in the ultra-premium cannabis space.”
Known for their consistency and efficacy, Medocann’s SEVEN products quickly earn patient loyalty — driving repeat demand and helping partners build a strong, premium presence in their markets.
A Future Built on Integrity, Innovation, and Trust
As regulatory frameworks evolve and consumer expectations sharpen, Medocann believes the cannabis industry is entering its quality-first era.
“We see cannabis moving from commodity to connoisseurship,” says Tessler. “The future belongs to companies that can consistently deliver safety, efficacy, and elevated experiences — not just once, but every single time.”
With its SMART indoor facility, pesticide-free commitment, and a growing international footprint, The Medocann Group is ready to meet that future — and help shape it.
Interested in partnering with Medocann? Visit www.medocann.com or contact us (info@medocann.com) to explore how we can bring ultra-premium craft cannabis to your market — together.
The post Cultivating Precision: Medocann’s Vision for Ultra-Premium Craft Cannabis on the Global Stage appeared first on Business of Cannabis.
Continue reading...
